FDA grants orphan drug designation to AstraZeneca’s surovatamig for follicular lymphoma
The FDA granted orphan drug designation to AstraZeneca’s surovatamig for follicular lymphoma. The status supports development for rare diseases but is only an early regulatory step.
The FDA granted orphan drug designation to surovatamig for follicular lymphoma. The status is aimed at supporting the development of treatments for rare diseases.
AstraZeneca said surovatamig received the designation for the treatment of follicular lymphoma. The decision was detailed in a post on the FDA's website.
The orphan drug designation for surovatamig in follicular lymphoma opens a rare disease angle in hematology. Progress updates on surovatamig’s clinical program will also matter, as orphan designation is only an early regulatory step rather than a sign of eventual approval.
AstraZeneca develops and markets pharmaceutical products across therapeutic areas including oncology, cardiovascular, renal, metabolic, rare diseases, and respiratory and immunology.